1. The generation and evaluation of TKO/hCD55/hTM/hEPCR gene-modified pigs for clinical organ xenotransplantation
- Author
-
Guoli Huai, Yong Wang, Jiaxiang Du, Zhenhui Cheng, Yuxuan Xie, Jia Zhou, Hongmei Tang, Yanyan Jiang, Xiangyang Xing, Shaoping Deng, and Dengke Pan
- Subjects
genetically modified pigs ,xenotransplantation ,TKO/hCD55/hTM/hEPCR ,infection ,DPF facility ,Immunologic diseases. Allergy ,RC581-607 - Abstract
IntroductionGenetically edited pigs, modified using CRISPR-Cas9 technology, hold promise as potential sources for xenotransplantation. However, the optimal combination of genetic modifications and their expression levels for initial clinical trials remains unclear. This study investigates the generation of TKO/hCD55/hTM/hEPCR (6GE) pigs and evaluates their compatibility with human immune and coagulation systems.MethodsThe 6GE pigs were generated through iterative genome editing and F1 generation breeding. Genotyping, flow cytometry, and immunohistochemistry confirmed the knockout of GGTA1, CMAH, and B4GALNT2. Expression levels of human genes (hCD55, hTM, hEPCR) were quantified. In vitro assays using aortic endothelial cells (pAECs) from 6GE pigs assessed human serum IgM and IgG binding, complement cytotoxicity, and thrombin-antithrombin (TAT) complex levels. Blood from gene-edited pigs was used for pathophysiological analysis.ResultsComplete knockout of GGTA1, CMAH, and B4GALNT2 was confirmed in 6GE pigs. The expression of hCD55 and hTM was approximately seven and thirteen times higher than in humans, respectively, while hEPCR levels were comparable to those in humans. In vitro, 6GE pAECs showed significantly reduced binding of human IgM and IgG compared to wild-type pAECs (IgG p
- Published
- 2025
- Full Text
- View/download PDF